EGRX 241220 5.00C (EGRX241220C5000) Stock Options, News & Quotes

0.45
0.000.00%

15min DelayClose Nov 27 16:00 ET

0.00High0.00Low

SymbolStock Name

Latest PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry

WatchlistPaper Trade

Comments

104830436

Oct 28 09:04

$Eagle Pharmaceuticals (EGRX.US)$ what happen... so sudden

104830436

Oct 9 09:35

$Eagle Pharmaceuticals (EGRX.US)$

Jaguar8

Aug 27 15:30

Eagle Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq

$Eagle Pharmaceuticals (EGRX.US)$
Eagle Pharmaceuticals (Nasdaq: EGRX) received a delisting notification from Nasdaq on August 21, 2024, due to its failure to timely file the Q2 2024 Form 10-Q. This follows a previous notice on August 1, 2024, where Nasdaq granted the company continued listing subject to specific conditions. Eagle must file its 2023 Annual Report by September 30, 2024, and both Q1 and Q2 2024 Form 10-Qs ...

Jaguar8

Apr 30 07:04

$Eagle Pharmaceuticals (EGRX.US)$
NEWS
Eagle Pharmaceuticals Announces a Trial in Progress Presentation of Phase 2/3 Study of Intravenous Amisulpride as Prevention of Postoperative Nausea and Vomiting in Pediatric Patients at the Upcoming Society for Ambulatory Anesthesia (SAMBA) 2024 Annual Meeting

Jaguar8

Apr 15 06:04

$Eagle Pharmaceuticals (EGRX.US)$
NEWS
Eagle Pharmaceuticals to Present Additional Data from Phase III Trial Demonstrating Sustained Response of Amisulpride for the Rescue Treatment of Postoperative Nausea and Vomiting (PONV) at the Upcoming ASPAN 2024 National Conference in Orlando, Florida
WOODCLIFF LAKE, N.J., April 15, 2024 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or the “Company”) today announced that data from the Company’s Phase III trial demonstrating the su...